PDE4 Inhibitor and CFTR Corrector Combination for Cystic Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cystic fibrosis, particularly for patients with CFTR mutations other than G551D, lack effective options as existing CFTR potentiators like ivacaftor are not approved for common mutations such as delF508, and there is a need for broader therapeutic solutions beyond the G551D mutation population.
Innovation Solution
The use of PDE4 inhibitors, specifically compounds like N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide or its enantiomers, in combination with CFTR potentiators like ivacaftor and correctors like lumacaftor, to treat cystic fibrosis by enhancing CFTR function across various mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CFTR potentiators like ivacaftor are used, then CFTR function is improved for G551D mutation, but the treatment is not effective for common mutations such as delF508
Solution Approach 1:
The patent combines PDE4 inhibitors with CFTR correctors and/or potentiators to create a multi-functional therapy that addresses multiple CFTR mutation types simultaneously. The PDE4 inhibitor component broadens the therapeutic approach beyond what single agents can achieve, making the treatment effective for both G551D and delF508 mutations.
Solution Approach 2:
The invention uses composite therapy combining multiple pharmacological agents (PDE4 inhibitor, CFTR corrector, and/or potentiator) to treat different CFTR mutation types. This composite approach leverages the complementary mechanisms of each agent to achieve broader mutation coverage while maintaining treatment effectiveness.
2Reliability
If PDE4 inhibitors are used alone, then CFTR activation occurs, but the treatment is insufficient for patients with folding mutations like delF508
Solution Approach 1:
The patent segments the treatment approach into distinct functional components: PDE4 inhibitors for CFTR activation, correctors for folding improvement, and potentiators for function enhancement. This segmentation allows each component to address specific aspects of CFTR dysfunction associated with different mutation types.
Solution Approach 2:
The invention merges PDE4 inhibitors with CFTR correctors and/or potentiators in a combination therapy that simultaneously addresses multiple pathological mechanisms. This merging creates a comprehensive treatment that works for both activation-deficient mutations and folding-deficient mutations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination therapy effectively treats cystic fibrosis by activating CFTR, improving chloride ion and water flow, thereby reducing mucus buildup and infection risk across a broader range of CFTR mutations, including delF508, offering a more comprehensive treatment approach.
Implementation Method 1
CFTR is activated by cAMP elevation and PKA activation, via PDE3 or PDE4 inhibition. Thus, a cAMP elevating agent, such as a PDE4 inhibitor, would be useful in the treatment of CF by activating CFTR.
Data Source
AI summary
Methods of treating cystic fibrosis by administering a PDE4 inhibitor in combination with one or more cystic fibrosis transmembrane conductance regulator (CFTR) potentiators, including ivacaftor, and/or one or more CFTR correctors, including lumacaftor. Pharmaceutical compositions, dosage forms, and kits suitable for use in methods of the invention are also disclosed.